Smooth Drug Development January 2026 News Release

Monthly News – January 2026

January showcased the breadth of our operational capacity across early- and late-phase studies.

• Phase I – Mucopolysaccharidosis: 28 subjects screened; 23 randomized
• Phase I – Ophthalmology: Last patient completed participation; database preparation for lock underway
• Phase I – Oncology: All site selection visits completed
• Phase III – HIV: Site selection visits completed
• Phase III – Hemorrhoids: Sites closed as part of completion activities
• Phase III – Gynecology: 62 patients randomized; additional sites initiated
• Phase IV – Spinal Muscular Atrophy: First Site Initiation Visit conducted

• Benign Prostatic Hyperplasia – Clinical phase completed
• Sedative and Anxiolytic Program – Multiple sites initiated
• Bacteriostatic Drug – Site activated
• Anticonvulsant Drug – First study period completed
• Type 2 Diabetes Mellitus – Site initiated
• Antitumor Drug – Patients randomized
• Duchenne Muscular Dystrophy – Final Clinical Study Report completed and submitted

Business Development News:

Participation in the 17th International Eurasian Pharmaceutical Forum reinforced Smooth Drug Development’s position as a trusted CRO partner across Eurasia.

With confirmed participation in BioChina, BIO International Convention, CPHI Milan, and World Vaccine Congress, 2026 is set to be a year of global engagement and strategic expansion.